UVA/UVB phototherapy for atopic dermatitis revisited

Area of Science:

• Dermatology
• Photobiology
• Clinical Therapeutics

Background:

• Atopic dermatitis (AD) is a common, genetically determined inflammatory skin condition.
• Current AD treatments include corticosteroids (CS), antihistamines, and immunosuppressors, with CS associated with side effects.
• Phototherapy (UVA/UVB) offers an alternative, often combined with CS to enhance efficacy.

Purpose of the Study:

• To compare the efficacy of UVA/UVB phototherapy versus UVA/UVB combined with topical corticosteroids for atopic dermatitis.
• To evaluate differences in therapeutic effect, treatment duration, remission length, UV dosage, and side effects between the two regimens.

Main Methods:

• A study involving 31 patients with moderate-to-severe AD (mean age 19).
• Group I (n=17) received UVA/UVB phototherapy; Group II (n=14) received UVA/UVB plus topical CS.
• Treatment involved 5 weekly sessions with standardized UVA and phototype-dependent UVB doses, with efficacy assessed via 10 severity and 10 topographic criteria.

Main Results:

• Both phototherapy regimens significantly reduced AD severity, erythema, excoriations, vesiculation, lichenification, xerosis, and pruritus.
• The combination of UVA/UVB and CS showed earlier signs of improvement.
• No significant difference in overall therapeutic efficacy or side effect frequency was found between groups.
• However, the addition of CS reduced treatment duration and total UVB dose.

Conclusions:

• UVA/UVB monotherapy and combination therapy with topical CS provide significant clinical improvement for AD patients.
• Adding topical CS to UVA/UVB phototherapy shortens treatment duration and lowers cumulative UVB exposure.
• The combination therapy does not impact remission duration or the frequency of observed side effects.